Transfer of the cytidine deaminase cDNA into hematopoietic cells

被引:20
作者
Flasshove, M [1 ]
Frings, W [1 ]
Schröder, JK [1 ]
Moritz, T [1 ]
Schütte, J [1 ]
Seeber, S [1 ]
机构
[1] Univ Essen Gesamthsch, Sch Med, W German Canc Ctr, Dept Internal Med Canc Res, D-45122 Essen, Germany
关键词
drug resistance; gene therapy; cytidine deaminase; retroviral vector; hematopoiesis; cytosine arabinoside;
D O I
10.1016/S0145-2126(99)00128-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to investigate whether transfer of the cytidine deaminase (CDD) cDNA would increase chemotherapy resistance to cytosine arabinoside (ara-C) we used a retroviral vector expressing both, neomycin phosphotransferase and the CDD cDNA, to transduce hematopoietic cells from cell lines and from murine bone marrow (BM). After coculture on producer clones with a viral titer of 1 x 10(5) CFU/ml and up to 3-fold increased CDD enzymatic activity, WEHI-3 cell line and primary hematopoietic cells were exposed to ara-C in clonogenic assays. A transduction efficiency of 34.8 +/- 6.2% could be determined for BM clonogenic progenitor cells by G418 resistance. We could observe significantly more colonies (77 +/- 3.1%) surviving from transduced primary BM cells than from mock cells (51.7 +/- 9.3%) at 10(-8) mol/l ara-C, At 10(-7) mol/l ara-C 8.7% of BM cells became absolutely resistant after retroviral transduction. Our data confirm that CDD represents another candidate gene for increasing resistance to cytotoxic drugs in hematopoietic cells. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1047 / 1053
页数:7
相关论文
共 41 条
[11]   Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice [J].
Eliopoulos, N ;
Bovenzi, V ;
Le, NLO ;
Momparler, LF ;
Greenbaum, M ;
Letourneau, S ;
Cournoyer, D ;
Momparler, RL .
GENE THERAPY, 1998, 5 (11) :1545-1551
[12]   Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA [J].
Flasshove, M ;
Banerjee, D ;
Leonard, JP ;
Mineishi, S ;
Li, MX ;
Bertino, JR ;
Moore, MAS .
HUMAN GENE THERAPY, 1998, 9 (01) :63-71
[13]  
FLASSHOVE M, 1995, BLOOD, V85, P566
[14]   A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs [J].
Galipeau, J ;
Benaim, E ;
Spencer, HT ;
Blakley, RL ;
Sorrentino, BP .
HUMAN GENE THERAPY, 1997, 8 (15) :1773-1783
[15]  
GANSBACHER B, 1990, CANCER RES, V50, P7820
[16]   Growth inhibition of granulocyte-macrophage colony-forming cells by human cytidine deaminase requires the catalytic function of the protein [J].
Gran, C ;
Boyum, A ;
Johansen, RF ;
Lovhaug, D ;
Seeberg, EC .
BLOOD, 1998, 91 (11) :4127-4135
[17]   Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells [J].
Hanenberg, H ;
Hashino, K ;
Konishi, H ;
Hock, RA ;
Kato, I ;
Williams, DA .
HUMAN GENE THERAPY, 1997, 8 (18) :2193-2206
[18]   IMPROVED GENE-EXPRESSION UPON TRANSFER OF THE ADENOSINE-DEAMINASE MINIGENE OUTSIDE THE TRANSCRIPTIONAL UNIT OF A RETROVIRAL VECTOR [J].
HANTZOPOULOS, PA ;
SULLENGER, BA ;
UNGERS, G ;
GILBOA, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3519-3523
[19]   Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation [J].
Hesdorffer, C ;
Ayello, J ;
Ward, M ;
Kaubisch, A ;
Vahdat, L ;
Balmaceda, C ;
Garrett, T ;
Fetell, M ;
Reiss, R ;
Bank, A ;
Antman, K .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :165-172
[20]  
HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1